RA
HAE icon

Rise Advisors’s Haemonetics HAE Stock Holding History

Rise Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-213
Closed -$10.4K – 666
2025
Q3 		$10.4K Hold
213
– – ﹤0.01% 978
2025
Q2 		$15.9K Hold
213
– – 0.01% 675
2025
Q1 		$13.5K Sell
213
-32
-13% -$2.18K 0.01% 775
2024
Q4 		$19.1K Hold
245
– – 0.01% 691
2024
Q3 		$19.7K Hold
245
– – 0.01% 703
2024
Q2 		$20.3K Hold
245
– – 0.01% 631
2024
Q1 		$20.9K Buy
+245
New +$19.2K 0.01% 619

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rise Advisors's HAE Position: Q4 2025 in Review

Rise Advisors sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 213 shares — an estimated $10.4K sold.

Rise Advisors first reported a position in HAE in Q1 2024 and held it in 7 quarters. The position peaked at $20.9K in Q1 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • Rise Advisors reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 213 Haemonetics shares in Q4 2025, an estimated $10.4K.
  • Rise Advisors first reported a position in Haemonetics in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's Haemonetics position peaked at $20.9K in Q1 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.